Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

John Wen Cheng Chang, Chun Liang Chou, Shiu Feng Huang, Hung Ming Wang, Jia Juan Hsieh, Todd Hsu, Yun Chung Cheung

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. Patient and methods: Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese male smoker with adenocarcinoma. He received cisplatin-based chemotherapy following craniotomy to remove his brain metastasis. Tumor progressed in both lung and left adrenal gland. He underwent second-line docetaxel chemotherapy. Tumor progressed again 7 months later. He was subsequently treated with gefitinib 250 mg QD. Complete regression of the lung tumor and partial response of the left adrenal gland mass was achieved. Nine months later, the left lower lobe lung tumor and left adrenal gland tumor progressed. A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20. Subsequent erlotinib 150 mg QD was administered. He experienced grade 1 skin rash, diarrhea and paronychia following erlotinib. Results: This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for a total of 18 months until the left adrenal gland tumor progressed. Conclusions: This case demonstrated that NSCLC bearing in-frame deletion in exon 19 of EGFR may respond to erlotinib treatment following gefitinib failure.

Original languageEnglish
Pages (from-to)414-417
Number of pages4
JournalLung Cancer
Volume58
Issue number3
DOIs
Publication statusPublished - Dec 1 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Adrenal Glands
Lung
Exons
Neoplasms
docetaxel
Adenocarcinoma
Paronychia
Drug Therapy
Craniotomy
Exanthema
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Cisplatin
gefitinib
Erlotinib Hydrochloride
Diarrhea
Therapeutics
Neoplasm Metastasis
Biopsy

Keywords

  • EGFR mutation
  • Erlotinib
  • Gefitinib
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Chang, J. W. C., Chou, C. L., Huang, S. F., Wang, H. M., Hsieh, J. J., Hsu, T., & Cheung, Y. C. (2007). Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer, 58(3), 414-417. https://doi.org/10.1016/j.lungcan.2007.05.018

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. / Chang, John Wen Cheng; Chou, Chun Liang; Huang, Shiu Feng; Wang, Hung Ming; Hsieh, Jia Juan; Hsu, Todd; Cheung, Yun Chung.

In: Lung Cancer, Vol. 58, No. 3, 01.12.2007, p. 414-417.

Research output: Contribution to journalArticle

Chang, JWC, Chou, CL, Huang, SF, Wang, HM, Hsieh, JJ, Hsu, T & Cheung, YC 2007, 'Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer', Lung Cancer, vol. 58, no. 3, pp. 414-417. https://doi.org/10.1016/j.lungcan.2007.05.018
Chang, John Wen Cheng ; Chou, Chun Liang ; Huang, Shiu Feng ; Wang, Hung Ming ; Hsieh, Jia Juan ; Hsu, Todd ; Cheung, Yun Chung. / Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. In: Lung Cancer. 2007 ; Vol. 58, No. 3. pp. 414-417.
@article{a823d80d5b254c698f7a53127bffc81d,
title = "Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer",
abstract = "Purpose: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. Patient and methods: Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese male smoker with adenocarcinoma. He received cisplatin-based chemotherapy following craniotomy to remove his brain metastasis. Tumor progressed in both lung and left adrenal gland. He underwent second-line docetaxel chemotherapy. Tumor progressed again 7 months later. He was subsequently treated with gefitinib 250 mg QD. Complete regression of the lung tumor and partial response of the left adrenal gland mass was achieved. Nine months later, the left lower lobe lung tumor and left adrenal gland tumor progressed. A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20. Subsequent erlotinib 150 mg QD was administered. He experienced grade 1 skin rash, diarrhea and paronychia following erlotinib. Results: This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for a total of 18 months until the left adrenal gland tumor progressed. Conclusions: This case demonstrated that NSCLC bearing in-frame deletion in exon 19 of EGFR may respond to erlotinib treatment following gefitinib failure.",
keywords = "EGFR mutation, Erlotinib, Gefitinib, NSCLC, EGFR mutation, Erlotinib, Gefitinib, NSCLC",
author = "Chang, {John Wen Cheng} and Chou, {Chun Liang} and Huang, {Shiu Feng} and Wang, {Hung Ming} and Hsieh, {Jia Juan} and Todd Hsu and Cheung, {Yun Chung}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.lungcan.2007.05.018",
language = "English",
volume = "58",
pages = "414--417",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

AU - Chang, John Wen Cheng

AU - Chou, Chun Liang

AU - Huang, Shiu Feng

AU - Wang, Hung Ming

AU - Hsieh, Jia Juan

AU - Hsu, Todd

AU - Cheung, Yun Chung

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. Patient and methods: Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese male smoker with adenocarcinoma. He received cisplatin-based chemotherapy following craniotomy to remove his brain metastasis. Tumor progressed in both lung and left adrenal gland. He underwent second-line docetaxel chemotherapy. Tumor progressed again 7 months later. He was subsequently treated with gefitinib 250 mg QD. Complete regression of the lung tumor and partial response of the left adrenal gland mass was achieved. Nine months later, the left lower lobe lung tumor and left adrenal gland tumor progressed. A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20. Subsequent erlotinib 150 mg QD was administered. He experienced grade 1 skin rash, diarrhea and paronychia following erlotinib. Results: This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for a total of 18 months until the left adrenal gland tumor progressed. Conclusions: This case demonstrated that NSCLC bearing in-frame deletion in exon 19 of EGFR may respond to erlotinib treatment following gefitinib failure.

AB - Purpose: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. Patient and methods: Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese male smoker with adenocarcinoma. He received cisplatin-based chemotherapy following craniotomy to remove his brain metastasis. Tumor progressed in both lung and left adrenal gland. He underwent second-line docetaxel chemotherapy. Tumor progressed again 7 months later. He was subsequently treated with gefitinib 250 mg QD. Complete regression of the lung tumor and partial response of the left adrenal gland mass was achieved. Nine months later, the left lower lobe lung tumor and left adrenal gland tumor progressed. A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20. Subsequent erlotinib 150 mg QD was administered. He experienced grade 1 skin rash, diarrhea and paronychia following erlotinib. Results: This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for a total of 18 months until the left adrenal gland tumor progressed. Conclusions: This case demonstrated that NSCLC bearing in-frame deletion in exon 19 of EGFR may respond to erlotinib treatment following gefitinib failure.

KW - EGFR mutation

KW - Erlotinib

KW - Gefitinib

KW - NSCLC

KW - EGFR mutation

KW - Erlotinib

KW - Gefitinib

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=35748985588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748985588&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.05.018

DO - 10.1016/j.lungcan.2007.05.018

M3 - Article

VL - 58

SP - 414

EP - 417

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -